

Listing of Claims:

1. A method of treating an intestinal disorder in a subject experiencing adherent invasive *E. coli* (AIEC) overgrowth of the intestine, comprising administering to the subject an effective amount of temocillin, or a pharmaceutically acceptable salt thereof.
2. The method of Claim 1, wherein the intestinal disorder is selected from irritable bowel syndrome (IBS) (e.g., diarrhea-associated irritable bowel syndrome (d-IBS), irritable bowel syndrome with constipation (c-IBS), alternating constipating and diarrhea irritable bowel syndrome), Crohn's disease, traveler's diarrhea, colitis, ulcerative colitis, pouchitis, and diverticulitis.
3. The method of Claim 1 or 2, wherein the intestinal disorder is Crohn's disease.
4. The method of any one of Claims 1 to 3, wherein the subject is administered a pharmaceutically acceptable salt of temocillin.
5. The method of any one of Claims 1 to 4, wherein the temocillin or pharmaceutically acceptable salt thereof is administered orally.
6. A method of modulating adherent invasive *E. coli* (AIEC) overgrowth in a subject in need thereof, comprising the step of administering to the subject an effective amount of temocillin, or a pharmaceutically acceptable salt thereof.
7. The method of Claim 6, wherein the AIEC overgrowth is in the subject's intestine.
8. The method of Claim 6 or 7, wherein the subject has an intestinal disorder.
9. The method of any one of Claims 6 to 8, wherein the subject has an intestinal disorder selected from irritable bowel syndrome (IBS) (e.g., diarrhea-associated irritable bowel syndrome (d-IBS), irritable bowel syndrome with constipation (c-IBS), alternating constipating and diarrhea irritable bowel syndrome), Crohn's disease, traveler's diarrhea, colitis, ulcerative colitis, and diverticulitis.

10. The method of any one of Claims 6 to 9, wherein the subject has Crohn's disease.
11. The method of any one of Claims 6 to 10, wherein modulation comprises a reduction in AIEC overgrowth.
12. The method of any one of Claims 6 to 11, wherein the temocillin or pharmaceutically acceptable salt thereof is administered orally.
13. A method of reducing intestinal inflammation caused by adherent invasive *E. coli* (AIEC) overgrowth in a subject in need thereof, comprising the step of administering to the subject an effective amount of temocillin, or a pharmaceutically acceptable salt thereof.
14. The method of Claim 13, wherein the subject has Crohn's disease.
15. A method of reducing one or more of diarrhea, fever, fatigue, abdominal pain and cramping, weight loss, and anemia in a subject having Crohn's disease, comprising orally administering to the subject an effective amount of temocillin, or a pharmaceutically acceptable salt thereof.
16. The method of Claim 15, wherein the subject is experiencing adherent invasive *E. coli* (AIEC) overgrowth of the intestine.
17. The method of any one of Claims 13 to 16, wherein the temocillin or pharmaceutically acceptable salt thereof is administered orally.